Asthma Therapeutics in Asia-Pacific Markets to 2023 - High Prevalence and Highly Priced Existing & Upcoming Biologics will Drive the Market

1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 8
1.2 List of Figures 8
2 Introduction 10
2.1 Disease Introduction 10
2.2 Epidemiology 10
2.3 Symptoms 11
2.4 Etiology and Pathophysiology 11
2.4.1 Pathophysiology 12
2.5 Diagnosis 14
2.6 Disease Stages 15
2.7 Prognosis 17
2.8 Treatment Guidelines and Options 18
2.8.1 Treatment Algorithm 18
2.8.2 Pharmacological Treatments 21
2.8.3 Non-Pharmacological Treatments 25
3 Marketed Products 27
3.1 Overview 27
3.2 ICS for the Maintenance Treatment of Asthma 27
3.2.1 Arnuity (fluticasone furoate) - GlaxoSmithKline 27
3.3 ICS-LABA Combination Therapy for the Maintenance Treatment of Asthma 28
3.3.1 Seretide/Adoair (fluticasone propionate and salmeterol xinafoate) - GlaxoSmithKline 28
3.3.2 Symbicort (budesonide and formoterol fumarate) - AstraZeneca, Co-promotion with Astellas Pharma 29
3.3.3 Relvar/Breo (vilanterol trifenatate and fluticasone furoate) - GlaxoSmithKline 30
3.3.4 Flutiform (fluticasone propionate and formoterol fumarate) - SkyePharma 31
3.4 Add-on Therapy to ICS or ICS-LABA Therapies for the Maintenance Treatment of Asthma 31
3.4.1 Xolair (omalizumab) - Novartis and Genentech 31
3.4.2 Montelukast Sodium - Merck & Co 33
3.4.3 Spiriva (tiotropium bromide) - Boehringer Ingelheim 34
3.4.4 Nucala (mepolizumab) - GlaxoSmithKline 35
3.5 Comparative Efficacy and Safety of Marketed Products 36
4 Pipeline Analysis 39
4.1 Overview 39
4.2 Pipeline by Stage of Development, Molecule Type, Route of Administration and Program Type 39
4.3 Pipeline by Molecular Target 41
4.4 Promising Pipeline Molecules 45
4.4.1 Reslizumab - Teva Pharmaceutical 45
4.4.2 Dupilumab - Regeneron/Sanofi 47
4.4.3 Tralokinumab - AstraZeneca 49
4.4.4 Benralizumab - AstraZeneca 51
4.4.5 Fevipiprant - Novartis 53
4.5 Comparative Efficacy and Safety of Pipeline Products 54
4.6 Product Competitiveness Framework 56
5 Clinical Trial Analysis 58
5.1 Failure Rate 58
5.1.1 Overall Failure Rate 58
5.1.2 Failure Rate by Phase and Molecule Type 60
5.1.3 Failure Rate by Phase and Molecular Target 61
5.2 Clinical Trial Duration 61
5.2.1 Clinical Trial Duration by Molecule Type 61
5.2.2 Clinical Trial Duration by Molecular Target 62
5.3 Clinical Trial Size 63
5.3.1 Patient Enrollment per Trial by Molecule Type, Molecular Target and Stage of Development 64
5.3.2 Patient Enrollment per Product by Molecule Type, Molecular Target and Stage of Development 65
5.4 Summary of Clinical Trial Metrics 67
6 Multi-Scenario Forecast 69
6.1 Geographical Markets 69
6.2 Asia-Pacific Market 70
6.3 India 72
6.3.1 Treatment Usage Patterns 72
6.3.2 Annual Cost of Therapy 73
6.3.3 Market Size 73
6.4 China 74
6.4.1 Treatment Usage Patterns 74
6.4.2 Annual Cost of Therapy 75
6.4.3 Market Size 76
6.5 Australia 77
6.5.1 Treatment Usage Patterns 77
6.5.2 Annual Cost of Therapy 78
6.5.3 Market Size 79
6.6 South Korea 80
6.6.1 Treatment Usage Patterns 80
6.6.2 Annual Cost of Therapy 81
6.6.3 Market Size 82
6.7 Japan 83
6.7.1 Treatment Usage Patterns 83
6.7.2 Annual Cost of Therapy 84
6.7.3 Market Size 85
7 Drivers and Barriers 87
7.1 Drivers 87
7.1.1 Rising Aging Population and Asthma Risk Factors 87
7.1.2 Promising Product Pipeline and Launch of First-in-Class Molecules 87
7.1.3 New Costly Market Entries 87
7.1.4 Diversified Healthcare Reform to Boost Market Growth 88
7.2 Barriers 88
7.2.1 Sales Erosion by Generics 88
7.2.2 Competition from Traditional Medicines 88
7.2.3 Treatment Regimen Adherence 88
7.2.4 Limited Understanding of Underlying Causes 88
7.2.5 Lack of Awareness and Affordability of High-Cost Biological Products 89
8 Deals and Strategic Consolidations 90
8.1 Licensing Deals 90
8.1.1 Deals by Region and Value 90
8.1.2 Number of Disclosed and Undisclosed Deals by Year, Aggregate Deal Value 91
8.1.3 Deal Value by Stage of Development, Molecule Type and Molecular Target 92
8.1.4 Key Licensing Deals 95
8.2 Co-development Deals 99
8.2.1 Deals by Region and Value 99
8.2.2 Number of Disclosed and Undisclosed Deals by Year, Aggregate Deal Value 100
8.2.3 Deal Value by Stage of Development, Molecule Type and Molecular Target 101
8.2.4 Key Co-development Deals 103
9 Appendix 106
9.1 All Pipeline Drugs by Phase of Development 106
9.1.1 Discovery 106
9.1.2 Preclinical 108
9.1.3 Investigational New Drug/ Clinical Trial Authorization-Filed 113
9.1.4 Phase I 114
9.1.5 Phase II 116
9.1.6 Phase III 118
9.1.7 Pre-registration 119
9.2 Summary of Multi-Scenario Market Forecasts to 2023 119
9.2.1 Asia-Pacific 119
9.2.2 China 119
9.2.3 India 120
9.2.4 Australia 120
9.2.5 South Korea 121
9.2.6 Japan 121
9.3 References 122
9.4 Abbreviations 128
9.5 Research Methodology 130
9.5.1 Secondary Research 131
9.5.2 Marketed Product Profiles 131
9.5.3 Late-Stage Pipeline Candidates 131
9.5.4 Comparative Efficacy and Safety Heat Map for Marketed and Pipeline Products 131
9.5.5 Product Competitiveness Framework 132
9.5.6 Pipeline Analysis 132
9.5.7 Forecasting Model 133
9.5.8 Deals Data Analysis 134
9.6 Contact Us 134
9.7 Disclaimer 134

List of Tables
1.1 List of Tables
Table 1: Asthma Therapeutics Market, Global, Classification of Asthma Severity in Children Aged 0-4 15
Table 2: Asthma Therapeutics Market, Global, Classification of Asthma Severity in Children Aged 5-11 16
Table 3: Asthma Therapeutics Market, Global, Classification of Asthma Severity in Those Aged 12 and over 16
Table 4: Asthma Therapeutics Market, Global, Classification of Asthma Severity According to GINA Guidelines (2002) 17
Table 5: Asthma Therapeutics, Global, Management of Chronic Asthma in Adults and Children Older than Five 19
Table 6: Asthma Diagnosis, Global, Symptoms and Management of Acute Asthma 20
Table 7: Asthma Trials, Global,Clinical Trial Endpoints 21
Table 8: Asthma Therapeutics Market, Global, Licensing Deals Valued Above $10m, 2006-2016 97
Table 9: Asthma Therapeutics Market, Global, Co-development Deals Valued Above $10m, 2006-2016 105
Table 10: Asthma Therapeutics Market, Global, All Pipeline Products, Discovery, 2016 106
Table 11: Asthma Therapeutics Market, Global, All Pipeline Products, Preclinical, 2016 108
Table 12: Asthma Therapeutics, Global, All Pipeline Products, IND/CTA-Filed, 2016 113
Table 13: Asthma Therapeutics Market, Global, All Pipeline Products, Phase I, 2016 114
Table 14: Asthma Therapeutics Market, Global, All Pipeline Products, Phase II, 2016 116
Table 15: Asthma Therapeutics Market, Global, All Pipeline Products, Phase III, 2016 118
Table 16: Asthma Therapeutics Market, Global, All Pipeline Products, Pre-registration, 2016 119
Table 17: Asthma Therapeutics Market, Asia-Pacific, Market Forecast, 2016-2023 119
Table 18: Asthma Therapeutics Market, China, Market Forecast, 2016-2023 119
Table 19: Asthma Therapeutics Market, India, Market Forecast, 2016-2023 120
Table 20: Asthma Therapeutics Market, Australia, Market Forecast, 2016-2023 120
Table 21: Asthma Therapeutics Market, South Korea, Market Forecast, 2016-2023 121
Table 22: Asthma Therapeutics Market, Japan, Market Forecast, 2016-2023 121

List of Figures
1.2 List of Figures
Figure 1: Asthma Therapeutics Market, Comparative Efficacy and Safety Heatmap for Marketed Products 38
Figure 2: Asthma Therapeutics Market, Global, Pipeline, 2016 41
Figure 3: Asthma Therapeutics Market, Global, Pipeline by Molecular Target, 2016 44
Figure 4: Asthma Therapeutics Market, Global, Pipeline by Molecular Target and Stage of Development, 2016 45
Figure 5: Asthma Therapeutics Market, Asia-Pacific, Reslizumab Forecast ($m), 2017-2023 47
Figure 6: Asthma Therapeutics Market, Asia-Pacific, Dupilumab Forecast ($m), 2019-2023 49
Figure 7: Asthma Therapeutics Market, Asia-Pacific, Tralokinumab Forecast ($m), 2019-2023 51
Figure 8: Asthma Therapeutics Market, Asia-Pacific, Benralizumab Forecast ($m), 2018-2023 53
Figure 9: Asthma Therapeutics Market, Asia-Pacific, Fevipiprant Forecast ($m), 2021-2023 54
Figure 10: Asthma Therapeutics Market, Comparative Efficacy and Safety Heatmap for Pipeline Products 55
Figure 11: Asthma Therapeutics Market, Competitor Matrix for Asthma Marketed and Pipeline Products, 2016 57
Figure 12: Asthma Therapeutics, Global, Average Clinical Trial Failure Rate (%), 2006-2016 59
Figure 13: Asthma Therapeutics, Global, Clinical Trial Failure Rate by Molecule Type, 2006-2016 60
Figure 14: Asthma Therapeutics, Global, Clinical Trial Failure Rate by Molecular Target, 2006-2016 61
Figure 15: Asthma Therapeutics, Global, Clinical Trial Duration by Phase and Molecule Type, 2006-2016 62
Figure 16: Asthma Therapeutics, Global, Clinical Trial Duration by Phase and Molecular Target, 2006-2016 63
Figure 17: Asthma Therapeutics, Global, Clinical Trial Size per Individual Trial by Stage of Development and Molecule Type, 2006-2016 64
Figure 18: Asthma Therapeutics, Global, Clinical Trial Size per Individual Trial by Stage of Development and Molecular Target, 2006-2016 65
Figure 19: Asthma Therapeutics, Global, Clinical Trial Size per Product by Stage of Development and Molecule Type, 2006-2016 66
Figure 20: Asthma Therapeutics, Global, Clinical Trial Size per Product by Stage of Development and Molecular Target, 2006-2016 67
Figure 21: Asthma Therapeutics Market, Global, Comparison of Average Trial Metrics by Phase and Molecule Type 68
Figure 22: Asthma Therapeutics Market, Global, Comparison of Average Trial Metrics by Phase and Molecular Target 68
Figure 23: Asthma Therapeutics Market, Asia-Pacific, Treatment Patterns, 2016-2023 70
Figure 24: Asthma Therapeutics Market, Asia-Pacific, Market Size ($bn), 2016-2023 71
Figure 25: Asthma Therapeutics Market, India, Treatment Usage Patterns (million), 2016-2023 72
Figure 26: Asthma Therapeutics Market, India, Annual Cost of Therapy ($), 2016-2023 73
Figure 27: Asthma Therapeutics Market, India, Market Size ($m), 2016-2023 74
Figure 28: Asthma Therapeutics Market, China, Treatment Usage Patterns, 2016-2023 75
Figure 29: Asthma Therapeutics Market, China, Annual Cost of Therapy ($), 2016-2023 76
Figure 30: Asthma Therapeutics Market, China, Market Size ($m), 2016-2023 77
Figure 31: Asthma Therapeutics Market, Australia, Treatment Usage Patterns (million), 2016-2023 78
Figure 32: Asthma Therapeutics Market, Australia, Annual Cost of Therapy ($), 2016-2023 79
Figure 33: Asthma Therapeutics Market, Australia, Market Size ($m), 2016-2023 80
Figure 34: Asthma Therapeutics Market, South Korea, Treatment Usage Patterns (million), 2016-2023 81
Figure 35: Asthma Therapeutics Market, South Korea, Annual Cost of Therapy ($), 2016-2023 82
Figure 36: Asthma Therapeutics Market, South Korea, Market Size ($m), 2016-2023 83
Figure 37: Asthma Therapeutics Market, Japan, Treatment Usage Patterns (million), 2016-2023 84
Figure 38: Asthma Therapeutics Market, Japan, Annual Cost of Therapy ($), 2016-2023 85
Figure 39: Asthma Therapeutics Market, Japan, Market Size ($m), 2016-2023 86
Figure 40: Asthma Therapeutics Market, Global, Licensing Deals by Region and Value, 2006-2016 91
Figure 41: Asthma Therapeutics Market, Global, Number of Disclosed and Undisclosed Licensing Deals by Year, Aggregate Deal Value ($m) and Aggregate Upfront Value ($m), 2006-2016 92
Figure 42: Asthma Therapeutics Market, Global, Licensing Deals by Stage of Development, Deal Value ($m) and Upfront Payment Value ($m), 2006-2016 93
Figure 43: Asthma Therapeutics Market, Global, Licensing Deals by Molecule Type, Stage of Development and Aggregate Deal Value ($m), 2006-2016 94
Figure 44: Asthma Therapeutics Market, Global, Licensing Deals by Molecular Target, Aggregate Deal Value ($m) and Aggregate Upfront Payment Value ($m), 2006-2016 95
Figure 45: Asthma Therapeutics Market, Global, Co-development Deals by Region, 2006-2016 99
Figure 46: Asthma Therapeutics Market, Global, Number of Disclosed and Undisclosed Co-development Deals by Year, Aggregate Deal Value ($m) and Aggregate Upfront Value ($m), 2006-2016 100
Figure 47: Asthma Therapeutics Market, Global, Co-development Deals by Stage of Development, Deal Value ($m) and Upfront Payment Value ($m), 2006-2016 101
Figure 48: Asthma Therapeutics Market, Global, Co-development Deals by Molecule Type, Stage of Development and Aggregate Deal Value ($m), 2006-2016 102
Figure 49: Asthma Therapeutics Market, Global, Co-development Deals by Molecular Target, Aggregate Deal Value ($m) and Aggregate Upfront Payment Value ($m), 2006-2016 103